T. Rowe Price Associates’s Kiora Pharmaceuticals KPRX Stock Holding History

T. Rowe Price Associates’s Portfolio KPRX Stock Details KPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-143	Closed	-$24K	–	3005
2022 Q2	$24K	Hold	143	–	–	﹤0.01%	2921
2022 Q1	$32K	Hold	143	–	–	﹤0.01%	2945
2021 Q4	$77K	Hold	143	–	–	﹤0.01%	2898
2021 Q3	$115K	Buy	+143	New	+$122K	﹤0.01%	2824

Other funds holding KPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

SFM

Spartan Fund Management Toronto, Ontario, Canada $30M AUM 11.98% 1-Year Est. Return

T. Rowe Price Associates's KPRX Position: Q3 2022 in Review

T. Rowe Price Associates sold out of Kiora Pharmaceuticals (KPRX) in Q3 2022, closing a stake of 143 shares — an estimated $24K sold.

T. Rowe Price Associates first reported a position in KPRX in Q3 2021 and held it in 4 quarters. The position peaked at $115K in Q3 2021. 9 funds tracked by Wall St. Rank hold KPRX as of Q3 2022.

T. Rowe Price Associates reported no remaining Kiora Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
T. Rowe Price Associates sold 143 Kiora Pharmaceuticals shares in Q3 2022, an estimated $24K.
T. Rowe Price Associates first reported a position in Kiora Pharmaceuticals in Q3 2021 and held it in 4 quarters.
T. Rowe Price Associates's Kiora Pharmaceuticals position peaked at $115K in Q3 2021.
9 funds tracked by Wall St. Rank held Kiora Pharmaceuticals as of Q3 2022.

Based on T. Rowe Price Associates's 13F filing for Q3 2022, filed 14 Nov 2022.